Douglas Fambrough

Douglas Fambrough is a co-founder of Dicerna Pharmaceuticals and joined the company as CEO in May 2010. Prior to joining Dicerna, Dr. Fambrough spent over a decade as a biotechnology venture capitalist with Oxford Bioscience Partners, one of Dicerna’s investors. At Oxford, he specialized in financing innovative life science technology companies such as the first generation RNA interference company, Sirna Therapeutics. Among his other investments are high-throughput DNA sequencing pioneer Solexa (acquired by Illumina); Xencor, which engineers antibody Fc domains to enhance drug properties; Rib-X Pharmaceuticals, a developer of antibiotics against multi-drug resistant pathogens; and Solstice Neurosciences, which markets the protein drug Myobloc for movement disorders. Prior to Oxford, Dr. Fambrough was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute).

Dr. Fambrough graduated from Cornell University and holds a Ph.D. in genetics from the University of California, Berkeley.

Douglas Fambrough is the CEO at Dicerna Pharmaceuticals. With a background in Biotechnology, Douglas Fambrough has a rich history of leadership and innovation.Douglas Fambrough studied Ph.D Genetics at University of California Berkeley. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.